NO321500B1 - Anvendelse av et tetrahydrobenz[cd]indol-6-karboksamid for fremstilling av et medikament for behandling av seksuell dysfunksjon - Google Patents

Anvendelse av et tetrahydrobenz[cd]indol-6-karboksamid for fremstilling av et medikament for behandling av seksuell dysfunksjon Download PDF

Info

Publication number: NO321500B1
Authority: NO; Norway
Prior art keywords: treatment; compounds; sexual dysfunction; tetrahydrobenz; indole
Prior art date: 1993-06-10

Application number

NO19942143A

Other languages

English (en)

Norwegian (no)

Other versions

NO942143D0 (no

NO942143L (no

Inventor

Mark Mortensen Foreman

J David Leander

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-10

Filing date

1994-06-09

Publication date

2006-05-15

1994-06-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1994-06-09 Publication of NO942143D0 publication Critical patent/NO942143D0/no

1994-12-12 Publication of NO942143L publication Critical patent/NO942143L/no

2006-05-15 Publication of NO321500B1 publication Critical patent/NO321500B1/no

Links

201000001880 Sexual dysfunction Diseases 0.000 title claims description 26
231100000872 sexual dysfunction Toxicity 0.000 title claims description 26
239000003814 drug Substances 0.000 title claims description 16
238000004519 manufacturing process Methods 0.000 title claims description 4
RTRIOEOJERCNTB-UHFFFAOYSA-N 1,2,2a,3-tetrahydrobenzo[cd]indole-6-carboxamide Chemical compound N1CC2CC=CC3=C2C1=CC=C3C(=O)N RTRIOEOJERCNTB-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 14
YTOJFUORFUYGSV-UHFFFAOYSA-N 4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboxamide Chemical compound C1=C(C(N)=O)C(CC(N(CCC)CCC)C2)=C3C2=CNC3=C1 YTOJFUORFUYGSV-UHFFFAOYSA-N 0.000 claims description 4
238000012360 testing method Methods 0.000 description 15
229940079593 drug Drugs 0.000 description 13
238000000034 method Methods 0.000 description 12
239000004480 active ingredient Substances 0.000 description 11
241000124008 Mammalia Species 0.000 description 10
239000000203 mixture Substances 0.000 description 9
206010047700 Vomiting Diseases 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
230000001568 sexual effect Effects 0.000 description 7
ZYVORBSWPVDTCX-UHFFFAOYSA-N 1,2,2a,3-tetrahydrobenzo[cd]indole Chemical class C1=CCC2CNC3=CC=CC1=C32 ZYVORBSWPVDTCX-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000002265 prevention Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
230000000069 prophylactic effect Effects 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000003826 tablet Substances 0.000 description 5
-1 aminocarboxamide compound Chemical class 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
208000019901 Anxiety disease Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
230000006399 behavior Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KJLFFCRGGGXQKE-UHFFFAOYSA-N 1h-indole-6-carboxamide Chemical compound NC(=O)C1=CC=C2C=CNC2=C1 KJLFFCRGGGXQKE-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
201000007930 alcohol dependence Diseases 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
229960002495 buspirone Drugs 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000000056 copulatory effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000013011 mating Effects 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
229960000317 yohimbine Drugs 0.000 description 2
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
CPXKXLSFUJLYFN-UHFFFAOYSA-N 8-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C(N(CCC)CCC)CCCC2=C1 CPXKXLSFUJLYFN-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001254607 Leander Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
NGCGMRBZPXEPOZ-HBBGHHHDSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)- Chemical compound CC(O)=O.C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NGCGMRBZPXEPOZ-HBBGHHHDSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000001243 acetic acids Chemical class 0.000 description 1
239000011149 active material Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001559 benzoic acids Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000005586 carbonic acid group Chemical group 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000001856 erectile effect Effects 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
238000011670 long-evans rat Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
229960003086 naltrexone Drugs 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
230000011514 reflex Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19942143A 1993-06-10 1994-06-09 Anvendelse av et tetrahydrobenz[cd]indol-6-karboksamid for fremstilling av et medikament for behandling av seksuell dysfunksjon NO321500B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7519893A	1993-06-10	1993-06-10

Publications (3)

Publication Number	Publication Date
NO942143D0 NO942143D0 (no)	1994-06-09
NO942143L NO942143L (no)	1994-12-12
NO321500B1 true NO321500B1 (no)	2006-05-15

Family

ID=22124191

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO19942143A NO321500B1 (no)	1993-06-10	1994-06-09	Anvendelse av et tetrahydrobenz[cd]indol-6-karboksamid for fremstilling av et medikament for behandling av seksuell dysfunksjon
NO991551A NO991551D0 (no)	1993-06-10	1999-03-30	Anvendelse av tetrahydrobenz(cd)indol-6-karboksamider i fremstilling av medikamenter for forebyggelse av emesis og behandling av seksuell dysfunksjon
NO993461A NO308693B1 (no)	1993-06-10	1999-07-14	Anvendelse av tetrahydrobenz(cd)indol-6-karboksamider for fremstilling av medikamenter for forebyggelse av emesis
NO20015806A NO20015806D0 (no)	1993-06-10	2001-11-28	Farmasöytisk preparat inneholdende et tetrahydrobenz[c,d]indol-6-karboksamid og anvendelse derav

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO991551A NO991551D0 (no)	1993-06-10	1999-03-30	Anvendelse av tetrahydrobenz(cd)indol-6-karboksamider i fremstilling av medikamenter for forebyggelse av emesis og behandling av seksuell dysfunksjon
NO993461A NO308693B1 (no)	1993-06-10	1999-07-14	Anvendelse av tetrahydrobenz(cd)indol-6-karboksamider for fremstilling av medikamenter for forebyggelse av emesis
NO20015806A NO20015806D0 (no)	1993-06-10	2001-11-28	Farmasöytisk preparat inneholdende et tetrahydrobenz[c,d]indol-6-karboksamid og anvendelse derav

Country Status (17)

Country	Link
US (1)	US5703112A (de)
EP (2)	EP1166783A3 (de)
JP (1)	JPH0748254A (de)
KR (2)	KR100367792B1 (de)
CN (2)	CN1072932C (de)
AU (1)	AU677317B2 (de)
CA (1)	CA2125088A1 (de)
CZ (2)	CZ285829B6 (de)
HK (1)	HK1043322B (de)
HU (1)	HUT71464A (de)
IL (1)	IL109872A (de)
NO (4)	NO321500B1 (de)
NZ (2)	NZ314570A (de)
RU (1)	RU2154476C2 (de)
TW (1)	TW258660B (de)
UA (2)	UA29415C2 (de)
ZA (1)	ZA943862B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2365782A1 (en)	1999-04-30	2000-11-09	William E. Pullman	Treatment of female arousal disorder
RU2154490C1 (ru) *	1999-07-15	2000-08-20	Кибрик Николай Давидович	Способ лечения сексуальных расстройств диэнцефального генеза у мужчин
GB0106446D0 (en) *	2001-03-15	2001-05-02	Vernalis Res Ltd	Chemical compounds
RU2200556C1 (ru) *	2001-12-05	2003-03-20	Северцев Владимир Алексеевич	Лекарственная форма налтрексона
AU2006254899B2 (en)	2005-06-08	2011-11-24	Sk Biopharmaceuticals Co., Ltd.	Treatment of sleep-wake disorders
DE602006012670D1 (de) *	2005-06-22	2010-04-15	Sk Holdings Co Ltd	Behandlung der sexuellen dysfunktion
RU2567801C2 (ru)	2009-06-22	2015-11-10	Ск Биофармасъютиклс Ко., Лтд.	Способы лечения и профилактики усталости
WO2011055944A2 (en)	2009-11-06	2011-05-12	Sk Holdings Co., Ltd.	Methods for treating fibromyalgia syndrome
KR101783632B1 (ko)	2009-11-06	2017-10-10	에스케이바이오팜 주식회사	주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US9610274B2 (en)	2010-06-30	2017-04-04	Sk Biopharmaceuticals Co., Ltd.	Methods for treating bipolar disorder
US9359290B2 (en)	2013-03-13	2016-06-07	Jazz Pharmaceuticals International Iii Limited	Treatment of cataplexy
PL3021838T3 (pl)	2013-07-18	2021-03-08	Jazz Pharmaceuticals Ireland Limited	Leczenie otyłości
US10195151B2 (en)	2016-09-06	2019-02-05	Jazz Pharmaceuticals International Iii Limited	Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3630072A4 (de)	2017-06-02	2021-03-10	Jazz Pharmaceuticals Ireland Limited	Verfahren und zusammensetzungen zur behandlung von übermässiger schläfrigkeit
US10940133B1 (en)	2020-03-19	2021-03-09	Jazz Pharmaceuticals Ireland Limited	Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4110339A (en) *	1977-11-25	1978-08-29	Eli Lilly And Company	4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4521421A (en) *	1983-09-26	1985-06-04	Eli Lilly And Company	Treatment of sexual dysfunction
US4576959A (en) *	1984-02-06	1986-03-18	Eli Lilly And Company	6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
CA1266482A1 (en) *	1984-05-24	1990-03-06	Carl Kaiser	6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
US4745126A (en) *	1987-03-12	1988-05-17	Eli Lilly And Company	Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
US4943428A (en) *	1987-07-10	1990-07-24	Wright State University	Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3809155A1 (de) *	1988-03-18	1989-09-28	Bayer Ag	1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) *	1989-04-11	1993-04-20	Eli Lilly And Company	Tetrahydrobenz(c,d)indole serotonin agonists
JP3005287B2 (ja) *	1989-07-13	2000-01-31	ファルマシア・アンド・アップジョン・カンパニー	（１，２ｎ）および（３，２ｎ）―炭素環式―２―アミノテトラリン誘導体
US5302612A (en) *	1990-02-26	1994-04-12	Eli Lilly And Company	6-substituted-hexahydrobenz[cd]indoles
IL97308A (en) *	1990-02-26	1996-10-31	Lilly Co Eli	6-Substituted-hexahydrobenz (cd) indoles process for their preparation and pharmaceutical compositions containing them
AU639536B2 (en) *	1990-03-15	1993-07-29	Pharmacia & Upjohn Company	Therapeutically useful heterocyclic indole compounds
US5258379A (en) *	1990-05-04	1993-11-02	Eli Lilly And Company	Method of inhibiting gastric acid secretion with n-arylpiperazines
US5096908A (en) *	1990-05-04	1992-03-17	Eli Lilly And Company	Method of inhibiting gastric acid secretion
US5229409A (en) *	1990-08-15	1993-07-20	Eli Lilly And Company	6-substituted-tetrahydrobenz[cd]indoles
US5244912A (en) *	1991-03-28	1993-09-14	Eli Lilly And Company	6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof

1994
- 1994-06-02 NZ NZ314570A patent/NZ314570A/xx unknown
- 1994-06-02 CZ CZ982818A patent/CZ285829B6/cs not_active IP Right Cessation
- 1994-06-02 CZ CZ941354A patent/CZ285762B6/cs not_active IP Right Cessation
- 1994-06-02 ZA ZA943862A patent/ZA943862B/xx unknown
- 1994-06-02 IL IL10987294A patent/IL109872A/xx not_active IP Right Cessation
- 1994-06-02 NZ NZ260667A patent/NZ260667A/en unknown
- 1994-06-03 CA CA002125088A patent/CA2125088A1/en not_active Abandoned
- 1994-06-04 TW TW083105103A patent/TW258660B/zh active
- 1994-06-06 UA UA94005243A patent/UA29415C2/uk unknown
- 1994-06-07 EP EP01201582A patent/EP1166783A3/de not_active Withdrawn
- 1994-06-07 EP EP94304103A patent/EP0633023A3/de not_active Withdrawn
- 1994-06-08 KR KR1019940012778A patent/KR100367792B1/ko not_active Expired - Fee Related
- 1994-06-08 AU AU64607/94A patent/AU677317B2/en not_active Ceased
- 1994-06-09 RU RU94020717/14A patent/RU2154476C2/ru not_active IP Right Cessation
- 1994-06-09 NO NO19942143A patent/NO321500B1/no unknown
- 1994-06-09 JP JP6127646A patent/JPH0748254A/ja active Pending
- 1994-06-09 HU HU9401730A patent/HUT71464A/hu unknown
- 1994-06-09 CN CN94106467A patent/CN1072932C/zh not_active Expired - Fee Related
1995
- 1995-11-17 US US08/560,174 patent/US5703112A/en not_active Expired - Fee Related
1999
- 1999-03-30 NO NO991551A patent/NO991551D0/no unknown
- 1999-07-14 NO NO993461A patent/NO308693B1/no unknown
2000
- 2000-06-27 UA UA2000063803A patent/UA37311C2/uk unknown
- 2000-10-31 CN CNB00132828XA patent/CN1170536C/zh not_active Expired - Fee Related
2001
- 2001-11-28 NO NO20015806A patent/NO20015806D0/no unknown
2002
- 2002-07-12 HK HK02105194.1A patent/HK1043322B/zh not_active IP Right Cessation
- 2002-08-31 KR KR1020020052257A patent/KR100367791B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1166783A3 (de)	2002-01-09
JPH0748254A (ja)	1995-02-21
KR100367791B1 (ko)	2003-02-14
NZ314570A (en)	2000-11-24
IL109872A0 (en)	1994-10-07
EP0633023A3 (de)	1995-03-29
ZA943862B (en)	1995-12-04
NO20015806D0 (no)	2001-11-28
HU9401730D0 (en)	1994-09-28
NO991551D0 (no)	1999-03-30
HK1043322A1 (en)	2002-09-13
UA37311C2 (uk)	2001-05-15
NZ260667A (en)	1997-05-26
HUT71464A (en)	1995-11-28
CN1342457A (zh)	2002-04-03
RU2154476C2 (ru)	2000-08-20
CZ285829B6 (cs)	1999-11-17
NO20015806L (no)	1994-12-12
NO993461L (no)	1994-12-12
CN1072932C (zh)	2001-10-17
EP0633023A2 (de)	1995-01-11
HK1043322B (zh)	2005-06-03
NO942143D0 (no)	1994-06-09
UA29415C2 (uk)	2000-11-15
CN1100634A (zh)	1995-03-29
AU677317B2 (en)	1997-04-17
NO991551L (no)	1994-12-12
IL109872A (en)	2000-12-06
NO308693B1 (no)	2000-10-16
RU94020717A (ru)	1996-08-27
EP1166783A2 (de)	2002-01-02
NO942143L (no)	1994-12-12
AU6460794A (en)	1994-12-15
CN1170536C (zh)	2004-10-13
KR100367792B1 (ko)	2003-02-19
NO993461D0 (no)	1999-07-14
CA2125088A1 (en)	1994-12-11
CZ135494A3 (en)	1994-12-15
CZ285762B6 (cs)	1999-11-17
US5703112A (en)	1997-12-30
TW258660B (de)	1995-10-01
KR950000146A (ko)	1995-01-03

Publication	Publication Date	Title
KR100469029B1 (ko)	2005-05-27	세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
AU761510B2 (en)	2003-06-05	Combination therapy for treatment of refractory depression
AU691844B2 (en)	1998-05-28	Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
RO116866B1 (ro)	2001-07-30	Compozitie pentru modularea raspunsului sexual
RU2154476C2 (ru)	2000-08-20	ПРИМЕНЕНИЕ ТЕТРАГИДРОБЕНЗ /cd/ИНДОЛ-6-КАРБОКСАМИДОВ ДЛЯ ПРЕДОТВРАЩЕНИЯ РВОТЫ, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ
KR950013450B1 (ko)	1995-11-08	치매 및 인식 장애 치료제
JPH07215865A (ja)	1995-08-15	閉経後女性の性欲を増進するための方法
US5462949A (en)	1995-10-31	Methods of inhibiting fertility in women
MX2010012179A (es)	2010-12-07	Composicion farmaceutica para el tratamiento de eyaculacion prematura.
EP0639072B1 (de)	1998-03-11	PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 5HT1 AGONISTISCHEN ALKYL SULPHONAMIDENFüR REKTALE VERABREICHUNGEN
IE911383A1 (en)	1991-11-06	Treatment
Clark et al.	1985	Central effects of RDS-127: Sexual behavior after intracerebroventricular administration and in vitro receptor binding studies
CZ288834B6 (cs)	2001-09-12	Farmaceutický prostředek k ošetřování desynchronizačních poruch
NO309964B1 (no)	2001-04-30	Anvendelse av melatoninderivater for fremstilling av et medikament for behandling av søvnforstyrrelser
WO2002074288A2 (en)	2002-09-26	Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide
FR2633831A1 (fr)	1990-01-12	Composition associant un antagoniste de 5ht3 a un inhibiteur de cyclo-oxygenase, son procede de fabrication et l'utilisation combinee d'un antagoniste de 5ht3 et d'un inhibiteur de cyclo-oxygenase en therapeutique
JP2000506860A (ja)	2000-06-06	自閉症の処置方法
AU719501B2 (en)	2000-05-11	Melatonin agonists for treating benign prostatic hyperplasia
US4363809A (en)	1982-12-14	Organic compounds
IE54257B1 (en)	1989-08-02	Trans-dihydrolisuride antipsychotic
JP2000506858A (ja)	2000-06-06	過剰攻撃性の処置方法
JP2000506528A (ja)	2000-05-30	不眠症の処置方法
HK1013796A (en)	1999-09-10	Preventing emesis and treating sexual dysfunction using tetrahydrobenz cd indole-6-carboxamides
CA2508477A1 (en)	1994-12-11	Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz ¬cd\| indole-6-carboxamides
ZA200101095B (en)	2002-05-08	New oral formulation for 5-ht4 agonists or antagonists.